Figure 3
From: Wnt/β-catenin controls follistatin signalling to regulate satellite cell myogenic potential
Wnt3a prime myoblasts for myogenic differentiation. (A) qPCR analysis of follistatin and myogenin expression levels in proliferating and differentiating myoblasts. Data are presented as the mean ± SEM (n = 3, **P < 0.01), normalized to GAPDH. (B) Western blot analysis of Pax7, myogenin, and follistatin expression in proliferating myoblasts following recombinant Wnt3a or control BSA protein treatments. (C) qPCR analysis of myogenin expression in proliferating myoblasts following recombinant Wnt3a, Dkk1, or control BSA protein treatments. Data are presented as the mean ± SEM (n = 3, **P < 0.01), normalized to GAPDH. (D) qPCR analysis of locus enrichment in chromatin immunoprecipitated with α-myogenin or control IgG antibodies from proliferating myoblasts following recombinant Wnt3a or control BSA protein treatments. Data are presented as the mean ± SEM (n = 3, **P < 0.01). (E) qPCR analysis of follistatin expression in myoblasts treated with siScr and BSA, siScr and Wnt3a, or siMyog and Wnt3a. Data are presented as the mean ± SEM (n = 3, **P < 0.01), normalized to GAPDH.